Inactive Instrument
Guided Therapeutics Inc Share Price OTC Bulletin Board
Stocks
US40171F1057
Advanced Medical Equipment & Technology
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 15/07 | Guided Therapeutics, Inc. Announces New Agreement With Yuanshuo Medical Instruments Corporation | CI |
| 16/06 | Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA | CI |
| Market Cap | 2.65Cr 2.33Cr 2.15Cr 1.98Cr 3.73Cr 256Cr 3.79Cr 26Cr 10Cr 125.26Cr 9.97Cr 9.75Cr 431.56Cr | P/E 2024 |
-3x | P/E 2025 | -12.7x |
|---|---|---|---|---|---|
| Enterprise Value | 2.94Cr 2.58Cr 2.38Cr 2.19Cr 4.14Cr 283.74Cr 4.2Cr 29Cr 11Cr 138.83Cr 11Cr 11Cr 478.31Cr | EV / Sales 2024 |
1,649x | EV / Sales 2025 | 64.4x |
| Free-Float |
63.48% | Yield 2024 * |
-
| Yield 2025 | - |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark Faupel
CEO | Chief Executive Officer | 70 | 06/03/2023 |
| Chief Tech/Sci/R&D Officer | 70 | 02/12/2010 |
| Director | Title | Age | Since |
|---|---|---|---|
Mark Faupel
BRD | Director/Board Member | 70 | 01/12/2016 |
John Imhoff
BRD | Director/Board Member | 76 | 10/04/2006 |
Michael James
CHM | Chairman | 67 | 01/10/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.17% | -0.43% | +26.88% | -2.24% | 20TCr | ||
| -1.33% | +0.47% | +5.82% | -17.71% | 14TCr | ||
| +2.24% | -13.25% | -31.90% | +1.58% | 13TCr | ||
| -0.59% | -1.97% | -57.77% | -18.13% | 6.51TCr | ||
| -0.85% | -7.40% | +11.13% | -8.26% | 4.89TCr | ||
| -2.02% | +0.99% | -24.39% | -32.55% | 4.49TCr | ||
| -0.91% | -2.82% | +14.27% | +4.58% | 3.68TCr | ||
| -3.10% | -4.20% | +24.35% | +27.80% | 3.51TCr | ||
| -0.19% | +0.06% | -23.00% | -9.43% | 2.86TCr | ||
| Average | -0.86% | -3.21% | -6.07% | -6.04% | 8.03TCr | |
| Weighted average by Cap. | -0.71% | -2.97% | -2.07% | -6.82% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 7T 6.14T 5.67T 5.22T 9.84T 7L 10T 67.81T 26.58T 3L 26.28T 25.71T 11.38L | 8L 7L 6L 6L 10.78L 7.4Cr 10.96L 74.3L 29.13L 3.62Cr 28.8L 28.17L 12Cr |
| Net income | -24.17L -21.19L -19.58L -18.01L -33.98L -23Cr -34.53L -2.34Cr -91.79L -11Cr -90.76L -88.78L -39Cr | -31.96L -28.01L -25.89L -23.81L -44.93L -31Cr -45.65L -3.1Cr -1.21Cr -15Cr -1.2Cr -1.17Cr -52Cr |
| Net Debt | 17.71L 15.52L 14.35L 13.2L 24.9L 17Cr 25.3L 1.72Cr 67.26L 8.36Cr 66.5L 65.05L 29Cr | 28.76L 25.21L 23.3L 21.43L 40.43L 28Cr 41.08L 2.79Cr 1.09Cr 14Cr 1.08Cr 1.06Cr 47Cr |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
















